Related Experiment Video
Updated: Jul 19, 2026
08:17
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
Published on: August 25, 2017
Steroid response in stable chronic obstructive pulmonary disease
Annals of Internal Medicine
|January 1, 1982
Summary
Methylprednisolone improved lung function in some patients with stable chronic obstructive pulmonary disease (COPD). Responders showed better bronchodilator response, suggesting a specific subgroup benefits from steroids.
Area of Science:
- Pulmonary Medicine
- Clinical Pharmacology
Background:
- Stable chronic obstructive pulmonary disease (COPD) management remains a challenge.
- Identifying predictors of treatment response is crucial for personalized therapy.
Purpose of the Study:
- To evaluate the efficacy of methylprednisolone in patients with stable COPD.
- To identify characteristics of patients who respond to corticosteroid treatment.
Main Methods:
- A double-blind, placebo-controlled crossover trial involving 46 patients with stable COPD.
- Treatment duration was 2 weeks of methylprednisolone (32 mg/d) or placebo, separated by a 2-week washout period.
- Forced expiratory volume in 1 second (FEV1.0) was the primary outcome measure.
Main Results:
- The group as a whole showed a significant increase in FEV1.0 after methylprednisolone compared to placebo.
- Eight patients (steroid responders) demonstrated substantial FEV1.0 improvement (>29%) with methylprednisolone.
- Steroid responders exhibited a significantly greater acute bronchodilator response compared to nonresponders (25% vs. 13%).
- No significant differences in baseline characteristics (age, sex, smoking history, symptoms, lung function, eosinophilia) were found between responders and nonresponders.
Conclusions:
- Methylprednisolone can significantly improve lung function in a subset of patients with stable COPD.
- Enhanced bronchodilator responsiveness may indicate a subgroup of COPD patients who benefit from corticosteroid therapy.
- Further research is warranted to elucidate the mechanisms and identify precise biomarkers for steroid responsiveness in COPD.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...